Kızılırmak Pınar, Öngen Zeki, Kayıkçıoğlu Meral, Tokgözoğlu Lale
Amgen Turkey, Medical Department, Istanbul, Turkey.
Istanbul University Cerrahpasa Faculty of Medicine, Cardiology Department, Istanbul, Turkey.
Turk Kardiyol Dern Ars. 2020 Mar;48(2):137-148. doi: 10.5543/tkda.2019.45156.
The aim of this study was to examine and present the effect of statin treatment on the low-density lipoprotein (LDL) cholesterol level of patients in Turkey by evaluating the data of studies conducted in the country.
Manuscripts published between January 1, 2008 and December 31, 2017 with terms 'LDL' and 'TURK' in the title or abstract and reporting LDL cholesterol data of patients treated with statins were evaluated for inclusion in the study. From the initial search result a total of 1795 papers, 39 manuscripts with 63 study arms were selected for analysis and the data of 3486 patients were included. Descriptive analysis was used to assess the data. Weighted averages of the data were also calculated.
The female/male ratio was 42/58. The mean age was 52.9±10.1 years. The proportion of patients with the recommended LDL cholesterol level of <70 mg/dL after treatment with statins was 15.3%;. In all, 10.2% of the patients who were prescribed a low-dose statin and 28.0% of those who were prescribed a high-dose statin had an LDL cholesterol of <70 mg/dL after treatment. Among patients who were being treated with statins for ≤2 months, 25.7% achieved an LDL cholesterol level of <70 mg/dL. Among those who were being treated with statins for 2-4 months and >4 months the proportion was 11.4% and 9.7%, respectively. The percentage of patients at the target level was 21.8%, 21.7%, 17.9%;, 8.6%, and 0.8% among those using atorvastatin, simvastatin, rosuvastatin, fluvastatin, and pravastatin, respectively.
In Turkey, only 15% of the patients who had received statin therapy had a LDL cholesterol level of <70 mg/dL. Revision of the current treatment should be considered to reach the target levels recommended in the guidelines, especially for patients with high cardiovascular risk.
本研究旨在通过评估在土耳其开展的研究数据，考察并呈现他汀类药物治疗对该国患者低密度脂蛋白（LDL）胆固醇水平的影响。
对2008年1月1日至2017年12月31日期间发表的、标题或摘要中含有“LDL”和“TURK”且报告了他汀类药物治疗患者LDL胆固醇数据的手稿进行评估，以纳入本研究。从初步检索结果的总共1795篇论文中，选择了39篇手稿（含63个研究组）进行分析，纳入了3486例患者的数据。采用描述性分析来评估数据，并计算了数据的加权平均值。
女性/男性比例为42/58。平均年龄为52.9±10.1岁。他汀类药物治疗后LDL胆固醇水平达到推荐的<70mg/dL的患者比例为15.3%。总体而言，服用低剂量他汀类药物的患者中有10.2%、服用高剂量他汀类药物的患者中有28.0%在治疗后LDL胆固醇水平<70mg/dL。在接受他汀类药物治疗≤2个月的患者中，25.7%的患者LDL胆固醇水平<70mg/dL。在接受他汀类药物治疗2 - 4个月和>4个月的患者中，这一比例分别为11.4%和9.7%。使用阿托伐他汀、辛伐他汀、瑞舒伐他汀、氟伐他汀和普伐他汀的患者中，达到目标水平的百分比分别为21.8%、21.7%、17.9%、8.6%和0.8%。
在土耳其，接受他汀类药物治疗的患者中只有15%的LDL胆固醇水平<70mg/dL。应考虑修订当前治疗方案，以达到指南中推荐的目标水平，尤其是对于心血管风险高的患者。
